N
Nancy L. Bartlett
Researcher at Washington University in St. Louis
Publications - 521
Citations - 31909
Nancy L. Bartlett is an academic researcher from Washington University in St. Louis. The author has contributed to research in topics: Brentuximab vedotin & Medicine. The author has an hindex of 71, co-authored 456 publications receiving 25253 citations. Previous affiliations of Nancy L. Bartlett include Alliance for Clinical Trials in Oncology & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu,Frederick L. Locke,Nancy L. Bartlett,Lazaros J. Lekakis,David B. Miklos,Caron A. Jacobson,Ira Braunschweig,Olalekan O. Oluwole,Tanya Siddiqi,Yi Lin,John M. Timmerman,Patrick J. Stiff,Jonathan W. Friedberg,Ian W. Flinn,Andre Goy,Brian T. Hill,Mitchell R. Smith,Abhinav Deol,Umar Farooq,Peter A. McSweeney,Javier Munoz,Irit Avivi,Januario E. Castro,Jason R. Westin,Julio C. Chavez,Armin Ghobadi,Krishna V. Komanduri,Ronald Levy,Eric D. Jacobsen,Thomas E. Witzig,Patrick M. Reagan,Adrian Bot,John J. Rossi,Lynn Navale,Yizhou Jiang,Jeff Aycock,Meg Elias,David Z. Chang,Jeff Wiezorek,William Y. Go +39 more
TL;DR: Patients with refractory large B‐cell lymphoma who received CAR T‐cell therapy with axi‐cel had high levels of durable response, with a safety profile that included myelosuppression, the cytokine release syndrome, and neurologic events.
Journal ArticleDOI
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke,Armin Ghobadi,Caron A. Jacobson,David B. Miklos,Lazaros J. Lekakis,Olalekan O. Oluwole,Yi Lin,Ira Braunschweig,Brian T. Hill,John M. Timmerman,Abhinav Deol,Patrick M. Reagan,Patrick J. Stiff,Ian W. Flinn,Umar Farooq,Andre Goy,Peter A. McSweeney,Javier Munoz,Tanya Siddiqi,Julio C. Chavez,Alex F. Herrera,Nancy L. Bartlett,Jeffrey S. Wiezorek,Lynn Navale,Allen Xue,Yizhou Jiang,Adrian Bot,John M. Rossi,Jenny J. Kim,William Y. Go,Sattva S. Neelapu +30 more
TL;DR: Long-term activity and safety outcomes of the ZUMA-1 study suggest that axicabtagene ciloleucel can induce durable responses and a median overall survival of greater than 2 years, and has a manageable relapsed or refractory disease or relapsed after autologous stem-cell transplantation.
Journal ArticleDOI
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert T. Chen +17 more
TL;DR: The ADC brentuximab vedotin was associated with manageable toxicity and induced objective responses in 75% of patients with relapsed or refractory HL after autologous stem-cell transplantation (auto-SCT).
Journal ArticleDOI
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
Roland Schmitz,George E. Wright,Da-Wei Huang,Calvin A. Johnson,James D. Phelan,James Q. Wang,Sandrine Roulland,Monica Kasbekar,Ryan M. Young,Arthur L. Shaffer,Daniel J. Hodson,Wenming Xiao,Xin Yu,Yandan Yang,Hong Zhao,Weihong Xu,Xuelu Liu,Bin Zhou,Wei Du,Wing C. Chan,Elaine S. Jaffe,Randy D. Gascoyne,Joseph M. Connors,Elias Campo,Armando López-Guillermo,Andreas Rosenwald,German Ott,Jan Delabie,Lisa M. Rimsza,Kevin Tay Kuang Wei,Andrew D. Zelenetz,Andrew D. Zelenetz,John P. Leonard,John P. Leonard,Nancy L. Bartlett,Nancy L. Bartlett,Bao Tran,Jyoti Shetty,Yongmei Zhao,Dan R. Soppet,Stefania Pittaluga,Wyndham H. Wilson,Louis M. Staudt +42 more
TL;DR: Analysis of genetic pathways suggested that MCD and BN2 DLBCLs rely on “chronic active” B‐cell receptor signaling that is amenable to therapeutic inhibition, and an algorithm was developed and implemented to discover genetic subtypes based on the co‐occurrence of genetic alterations.
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes,Nancy L. Bartlett,John P. Leonard,Dana A. Kennedy,Carmel M. Lynch,Eric L. Sievers,Andres Forero-Torres +6 more
TL;DR: Brentuximab vedotin induced durable objective responses and resulted in tumor regression for most patients with relapsed or refractory CD30-positive lymphomas in this phase 1 study.